Molly Harper insider trades: Catalyst Pharmaceuticals (CPRX) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Molly reports to the SEC
Open-market buys and sales
4 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Dec 12, 2025 | CPRX | ↓ Sell | 26,746 | $23.25 | $622K | Direct | Dec 16, 2025 (4d) |
| Nov 27, 2024 | CPRX | ↓ Sell | 17,500 | $22.00 | $385K | Direct | Nov 29, 2024 (2d) |
| Jun 3, 2024 | CPRX | ↓ Sell | 5,333 | $16.30 | $87K | Direct | Jun 5, 2024 (2d) |
| Dec 15, 2023 | CPRX | ↓ Sell | 14,000 | $14.39 | $201K | Direct | Dec 19, 2023 (4d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other CPRX insiders
Open-market trades in the last 12 months
About Molly Harper's insider trades
Molly Harper is a director at Catalyst Pharmaceuticals (CPRX). Since Dec 15, 2023, Molly has reported no open-market purchases and 4 sales worth $1.3M on SEC Form 4. In the last 12 months: 1 sale ($622K).
Their filings also include option exercises (11 filings), grants and awards (6 filings), shares returned to the company (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every CPRX insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.